<DOC>
	<DOC>NCT01535664</DOC>
	<brief_summary>The purpose of this study is to determine changes on overall gait as well as in multiple gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are receiving the medication consistently for at least two weeks prior to screening.</brief_summary>
	<brief_title>An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)</brief_title>
	<detailed_description>Longitudinal study design</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Diagnosis of multiple sclerosis Receiving AmpyraÂ® consistently for at least 2 weeks prior to the screening visit No history of seizures except simple febrile seizures Sexually active woman of childbearing potential who is not surgically sterile, &lt;two years postmenopause or is not using effective birth control methods Subject who is pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>